Welcome to our dedicated page for VISKASE COS news (Ticker: VKSC), a resource for investors and traders seeking the latest updates and insights on VISKASE COS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VISKASE COS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VISKASE COS's position in the market.
Icahn Enterprises reported a net loss of $183 million ($0.57 per unit) for the twelve months ending December 31, 2022, an improvement from $518 million in the prior year. Revenues increased to $14.1 billion from $11.3 billion in 2021. Adjusted EBITDA rose to $758 million compared to $273 million year-over-year. In Q4 2022, revenues were $3.1 billion with a net loss of $255 million. Despite a loss in Adjusted EBITDA of $54 million for the quarter, this marked an improvement from the previous year's loss of $443 million. The Indicative Net Asset Value grew by $522 million to $5.6 billion. The board declared a quarterly distribution of $2.00 per unit, continuing a consistent distribution trend since 2005.
FAQ
What is the market cap of VISKASE COS (VKSC)?
